Flex Pharma Presenting Data on Promising Muscle Cramp Therapeutic Agent FLX-787 at Neuroscience 2015
Flex Pharma, Inc., a biotechnology company focused on therapies for muscle cramps and spasms associated with neuromuscular conditions, recently…
Articles by Patricia Silva, PhD
Study Finds Fatigue to Be the Most Common Driver of Employment Changes in Multiple Sclerosis Patients
In a recent study published in the International Journal of MS Care, a team of researchers determined…
RIKNO 1.0: New Risk Knowledge Assessment Tool for Patients with Relapsing-Remitting Multiple Sclerosis
A recently published study in the journal PLOS One reported a new tool to assess risk knowledge…
Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting Multiple Sclerosis
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients…
GATE Trial Supports Generic Glatiramer Acetate as an Alternative Therapy for Relapsing-Remitting Multiple Sclerosis
The Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) seems to be the first phase 3 clinical…
Researchers Develop Potential Inhibitors for Proteins Involved in Cancer, Multiple Sclerosis and other Autoimmune Diseases
A new study published in the Journal of Biological Chemistry revealed novel potential inhibitors of specific proteins…
EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for Relapsing–Remitting Multiple Sclerosis
EMD Serono, the U.S. biopharmaceutical division of Merck KGaA, Darmstadt, Germany, recently announced that the results of the 15…
Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl)
Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results…
Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015
A session titled “Late Breaking News” was featured at the 31st Congress of the European Committee for Treatment and Research…
Importance of Microbiota in MS Development Explored in ECTRIMS 2015 Presentation
Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st…
Prof. Jorge Correale Reviews Environmental Factors Associated with Multiple Sclerosis at ECTRIMS 2015
Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress…
Update on Alemtuzumab (Genzyme’s Lemtrada) Clinical Trial Data Presented at ECTRIMS 2015
Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…
EXCLUSIVE: Genentech/Roche Interview with MS News Today on Promising MS Therapy Ocrelizumab #ECTRIMS 2015
Dr. Peter Chin, a renowned neurologist and Principal Medical Director of Global Neuroscience Development at Genentech, a leading biotechnology…
Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015
Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis…
Biometrica MS Launched at ECTRIMS 2015 to Support Routine Multiple Sclerosis Care
Biometrica MS, a technology that provides an easy to use service for neurologists to quantify lesion load as well as…
EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015
A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr.
New 3-Times-Per-Week Regimen For Teva’s Copaxone Safe, Effective & Increases Patient Compliance #ECTRIMS2015
A Satellite Symposia entitled “Discovering a new world in MS” presented by Teva Neuroscience was held yesterday, October 8 at…
Potential MS Drug Cladribine Reported To Have No Impact on Cancer Incidence
A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine…
Discovering a New World in MS Through Genomics, ECTRIMS 2015
A Satellite Symposia entitled “Discovering a new world in MS” supported by Teva Neuroscience was held yesterday, October 8,…
MS Care: A Hot Topic at #ECTRIMS2015
Three “Hot Topic Sessions” on multiple sclerosis will take place this afternoon (17:00 – 17:45 h, GMT + 1h) at…
Aubagio (Teriflunomide) Slows Brain Atrophy in Patients with Relapsing Multiple Sclerosis
Genzyme recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing…
Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015
Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatment for relapsing-remitting…
Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015
Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1…
Teva Pharmaceuticals to Present New Data on Multiple Sclerosis Drugs Copaxone and Laquinimod at ECTRIMS 2015
The world’s largest generic medicines manufacturer, Teva Pharmaceutical, is at the 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)…
Good Cholesterol Helps Prevent Brain Lesion Formation in Multiple Sclerosis
A number of studies have previously suggested a negative effect of high cholesterol levels on the development of brain lesions…
ECTRIMS 2015 Congress: a Look at Young Investigator Session II
The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) begins today, October 7, 2015 at…
Genzyme to Present vs.MS Global Survey Data on Relapsing Multiple Sclerosis Challenges at ECTRIMS
Genzyme recently announced a novel worldwide initiative called vs.MS, whose goal is to increase awareness of the psychical and emotional…
ECTRIMS 2015 Congress: a Look at Young Investigator Session I
The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October…
Icometrix Collaborates with Novartis on MSmetrix Software Application, New Data at Upcoming ECTRIMS 2015 Conference
Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement…
PCORI Board Approves $83 Million for Research on Multiple Sclerosis, Hepatitis C and Rare Diseases
The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approved an $83 million grant to support 26 patient-centered, comparative…